Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | President, Pharma Services | March 01, 2022 | March 04, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date March 01, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,443 |
Reported balance
After 2022-03-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 11,677 · Balance 33,443 F1: On March 1, 2022, Ms. Wallar was granted 11,677 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. F2: This balance includes 104 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares wereacquired in transactions exempt from Section 16b-3. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.41 · Expires 2029-03-01 | Direct | 28,506 |
Reported balance
After 2022-03-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-03-01 · Grant · Acquired 28,506 · Balance 28,506 F9: On March 1, 2022, Ms. Wallar was granted 28,506 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.22 · Expires 2023-04-19 | Direct | 6,667 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 6,667 F3: On April 19, 2018, Ms. Wallar was granted 20,000 stock options. The options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 · Expires 2023-12-12 | Direct | 8,334 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 8,334 F4: On December 12, 2018, Ms. Wallar was granted 25,000 stock options. The options vested ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.83 · Expires 2026-05-01 | Direct | 7,153 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 7,153 F5: On May 1, 2019, Ms. Wallar was granted 9,537 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.34 · Expires 2027-05-01 | Direct | 7,879 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,879 F6: On May 1, 2020, Ms. Wallar was granted 7,879 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.99 · Expires 2028-05-01 | Direct | 8,595 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 8,595 F7: On May 1, 2021, Ms. Wallar was granted 8,595 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.95 · Expires 2028-07-05 | Direct | 10,126 |
Reported balance
Holding disclosure · report date 2022-03-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 10,126 F8: On July 5, 2021, Ms. Wallar was granted 10,126 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 1, 2022, Ms. Wallar was granted 11,677 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date.
F2: This balance includes 104 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares wereacquired in transactions exempt from Section 16b-3.
F3: On April 19, 2018, Ms. Wallar was granted 20,000 stock options. The options vested ratably over the first three anniversary dates of the grant date.
F4: On December 12, 2018, Ms. Wallar was granted 25,000 stock options. The options vested ratably over the first three anniversary dates of the grant date.
F5: On May 1, 2019, Ms. Wallar was granted 9,537 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F6: On May 1, 2020, Ms. Wallar was granted 7,879 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F7: On May 1, 2021, Ms. Wallar was granted 8,595 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F8: On July 5, 2021, Ms. Wallar was granted 10,126 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F9: On March 1, 2022, Ms. Wallar was granted 28,506 stock options. These options vest ratably over the first four anniversary dates of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2022 Filed Mar 4, 2022 00:56 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 28,506 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001077183-22-000038 · wf-form4_164635538738847.xml · derivative · entry 8 Wallar Gina M · CIK 0001869819 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,506 Underlying: Common Stock · 28,506 shares Expires 2029-03-01 F9 · derivative.exercise_date: On March 1, 2022, Ms. Wallar was granted 28,506 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 4, 2022 00:56 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 11,677 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000038 · wf-form4_164635538738847.xml · nonDerivative · entry 1 Wallar Gina M · CIK 0001869819 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,443 F1 · shares: On March 1, 2022, Ms. Wallar was granted 11,677 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. F2 · balance_after: This balance includes 104 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares wereacquired in transactions exempt from Section 16b-3. Read SEC document |
| December 31, 2021 Filed Feb 9, 2022 00:12 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherCommon Stock | 363 | $35.28 | $12,806.64 |
DisclosureSEC source: 0001077183-22-000008 · wf-form5_164436552625449.xml · nonDerivative · entry 1 Wallar Gina M · CIK 0001869819 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,662 F1 · kind: These shares were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the year ended December 31, 2021. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| December 30, 2021 Filed Dec 30, 2021 23:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 15,286 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000280 · wf-form4_164090552671834.xml · nonDerivative · entry 1 Wallar Gina M · CIK 0001869819 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,299 F1 · kind: On December 30, 2021, Ms. Wallar was granted 15,286 restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022. Read SEC document |
| July 05, 2021 Filed Jul 7, 2021 23:01 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 10,126 | $43.95 Strike: $43.95 | $445,037.70 |
DisclosureSEC source: 0001077183-21-000186 · wf-form4_162569888733988.xml · derivative · entry 7 Wallar Gina M · CIK 0001869819 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,126 Underlying: Common Stock · 10,126 shares Expires 2028-07-05 F6 · derivative.exercise_date: On July 5, 2021, Ms. Wallar was granted 10,126 stock options. The options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| July 05, 2021 Filed Jul 7, 2021 23:01 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 1,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-21-000186 · wf-form4_162569888733988.xml · nonDerivative · entry 1 Wallar Gina M · CIK 0001869819 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,013 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.